BlackRock’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-5,723
Closed -$100K 5411
2020
Q4
$100K Sell
5,723
-6,243
-52% -$87.6K ﹤0.01% 4590
2020
Q3
$140K Sell
11,966
-7,001
-37% -$92.9K ﹤0.01% 4471
2020
Q2
$247K Sell
18,967
-988
-5% -$11.9K ﹤0.01% 4336
2020
Q1
$185K Buy
19,955
+5,695
+40% +$79.6K ﹤0.01% 4244
2019
Q4
$237K Buy
14,260
+5,507
+63% +$89.3K ﹤0.01% 4295
2019
Q3
$146K Sell
8,753
-50,763
-85% -$702K ﹤0.01% 4369
2019
Q2
$818K Sell
59,516
-1,217,999
-95% -$18.6M ﹤0.01% 4069
2019
Q1
$22M Sell
1,277,515
-23,236
-2% -$368K ﹤0.01% 2700
2018
Q4
$16.6M Sell
1,300,751
-9,347
-0.7% -$142K ﹤0.01% 2819
2018
Q3
$21.3M Buy
1,310,098
+30,774
+2% +$440K ﹤0.01% 2839
2018
Q2
$16.5M Buy
1,279,324
+116,814
+10% +$1.58M ﹤0.01% 2972
2018
Q1
$14.5M Buy
1,162,510
+74,565
+7% +$908K ﹤0.01% 2936
2017
Q4
$15.2M Buy
1,087,945
+65,718
+6% +$963K ﹤0.01% 2923
2017
Q3
$17.2M Sell
1,022,227
-7,134
-0.7% -$116K ﹤0.01% 2888
2017
Q2
$17.3M Buy
1,029,361
+25,954
+3% +$388K ﹤0.01% 2873
2017
Q1
$15.5M Buy
1,003,407
+1,001,222
+45,823% +$14.3M ﹤0.01% 2905
2016
Q4
$33K Sell
2,185
-278
-11% -$3.9K ﹤0.01% 3106
2016
Q3
$31K Buy
2,463
+402
+20% +$4.04K ﹤0.01% 3163
2016
Q2
$18K Sell
2,061
-1,021
-33% -$10K ﹤0.01% 3299
2016
Q1
$30K Buy
3,082
+2,157
+233% +$22.1K ﹤0.01% 2643
2015
Q4
$11K Buy
925
+622
+205% +$7.7K ﹤0.01% 2871
2015
Q3
$4K Hold
303
﹤0.01% 3098
2015
Q2
$4K Hold
303
﹤0.01% 3171
2015
Q1
$4K Buy
+303
New +$4.12K ﹤0.01% 3081
2014
Q1
Sell
-151
Closed -$3K 3189
2013
Q4
$3K Buy
+151
New +$2.67K ﹤0.01% 3117

BlackRock's OXFD Position: Q1 2021 in Review

BlackRock sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q1 2021, closing a stake of 5,723 shares — an estimated $100K sold.

BlackRock first reported a position in OXFD in Q4 2013 and held it in 25 quarters. The position peaked at $22M in Q1 2019. 0 funds tracked by Wall St. Rank hold OXFD as of Q1 2021.

  • BlackRock reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q1 2021 after selling out during the quarter.
  • BlackRock sold 5,723 Oxford Immunotec Global PLC Ordinary Shares shares in Q1 2021, an estimated $100K.
  • BlackRock first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q4 2013 and held it in 25 quarters.
  • BlackRock's Oxford Immunotec Global PLC Ordinary Shares position peaked at $22M in Q1 2019.
  • 0 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q1 2021.

Based on BlackRock's 13F filing for Q1 2021, filed 7 May 2021.